Stock Taper
NCEL
NEWCELX LTD.
NASDAQ
$3.25
▼ DOWN 2.99% (-0.10)

KEY STATISTICS

Market Cap$1.46 M
52w High$24.60
52w Low$1.83
Dividend Yield
Frequency
P/E-0.59
Volume4.28K
Shares Out.450.00K

COMPANY

LEADERSHIP

Ronen Twito
CHIEF EXECUTIVE
Ronen Twito

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 24, 2025
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
11

UPCOMING EARNINGS

DateMar 3, 2027
DayWednesday
Rev. Est.
MAR
3
WED

SPLIT RECORD

DATETYPERATIO
2025-10-31Reverse1:10
2024-09-27Reverse1:40

PRICE

$3.25 ▼ DOWN 2.99% (−$0.10)
OVERLAYS
$3.15$3.23$3.309:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.25

About NewcelX Ltd.

https://newcelx.net ↗

NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.

INDUSTRY

Biotechnology

A PRODUCT NEWCELX LTD. IS KNOWN FOR

IsletRx
IsletRx

IsletRx, NewcelX's lead clinical program, is a cell therapy in development for Type 1 Diabetes that aims to restore insulin production by transplanting stem cell-derived islet cells.

RATINGS SNAPSHOT

Overall rating: A

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets5
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score4

INSIDER TRADES

DIRECTOR
Samuel Olivier
Purchase · 81.8K shares
2026-04-27
DIRECTOR
Samuel Olivier
Purchase · 114.5K shares
2026-04-27
DIRECTOR, 10 PERCENT OWNER, OFFICER: CSO AND DIRECTOR
Revel Michel
Purchase · 76.4K shares
2026-04-27
DIRECTOR, 10 PERCENT OWNER, OFFICER: CSO AND DIRECTOR
Revel Michel
Purchase · 54.5K shares
2026-04-27

SECTORS PEERS

PEERPRICE
PRE$25.78COMPARE
SABS$3.71COMPARE
SRZN$22.15COMPARE
CELU$1.57COMPARE
KTTA$0.60COMPARE
GTBP$0.63COMPARE
NKGN$0.04COMPARE
MLEC$0.36COMPARE